Human Genome estimates upped by JMP

Human Genome Sciences Inc. was reiterated by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $21 per share following the company's earnings, which beat estimates. On the results, JMP raised its estimates for 2005 revenues to $6.0 million from $4.1 million and a narrower loss per share of $1.91 from $1.93. Human Genome shares Tuesday gained $0.73, or 5.16%, to close at $14.88 on volume of 3,916,071 shares versus the three-month running average of 1,747,210 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.